HaiRui

Hairui Biopharma is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the discovery and development of next-generation small molecule drugs for oncology and immunology. The company utilizes a proprietary structure-based drug design (SBDD) platform to target challenging biological pathways, with a particular focus on the KRAS/MAPK signaling axis and exon 20 insertion mutations in lung cancer. Its lead program, HR-1402, is a potent dual inhibitor of EGFR and HER2 exon 20 insertions currently in Phase 1/2 clinical trials. Additionally, Hairui is advancing a robust pipeline that includes a KRAS G12C inhibitor (HR-1801) and a TYK2 inhibitor (HR-0701) for autoimmune conditions. The company aims to provide high-efficacy, low-toxicity precision medicines to address significant unmet medical needs globally.